This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Masimo's (MASI) MightySat Pulse Oximeter Receives FDA Approval
by Zacks Equity Research
Masimo's (MASI) MightySat Medical Pulse Oximeter receives FDA clearance, which makes it the first FDA-approved pulse oximeter to be available OTC.
Veeva (VEEV) & Boehringer Partner to Boost Animal Healthcare
by Zacks Equity Research
Veeva (VEEV) collaborates with Boehringer to offer its Veeva Vault Clinical and Veeva Vault RIM applications to improve animals??? healthcare via technological upliftment.
Avantor (AVTR) Q4 Earnings & Revenues Top Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft fourth-quarter performance.
QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall
by Zacks Equity Research
Despite solid performances by the Labs segment and China and Other regions, QuidelOrtho (QDEL) misses earnings and revenue estimates by 41.8% and 6.9%, respectively.
DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.
GE Healthcare (GEHC), MedQuest Partner to Boost Imaging Field
by Zacks Equity Research
GE Healthcare (GEHC) collaborates with MedQuest to optimize outpatient imaging networks. With AI capabilities from GE Healthcare, MedQuest is likely to provide better solutions in the imaging space.
Cooper Companies (COO), Fulgent Unite to Boost Genetic Testing
by Zacks Equity Research
Cooper Companies (COO) collaborates with Fulgent Genetics to boost newborn genetic screenings. CBR by Cooper Surgical is likely to provide a variety of genetic testing options to its families.
Zacks Industry Outlook Highlights Elevance Health, Cencora and HealthEquity
by Zacks Equity Research
Elevance Health, Cencora and HealthEquity have been highlighted in this Industry Outlook article.
The Zacks Analyst Blog Highlights Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health
by Zacks Equity Research
Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health are included in this Analyst Blog.
Top Research Reports for Johnson & Johnson, Walt Disney & Uber
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and Uber Technologies, Inc. (UBER).
Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
by Zacks Equity Research
Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.
Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System
by Zacks Equity Research
Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.
Haemonetics (HAE) Q3 Earnings Top Estimates, 2024 View Raised
by Zacks Equity Research
Haemonetics' (HAE) proprietary technology, Persona, continues to gain momentum in the third quarter.
3 Medical Services Stocks to Buy Amid Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and HQY are set to gain the most. However, staffing shortages continue to disrupt the growth trend.
Molina Healthcare (MOH) Q4 Earnings Beat on Premium Growth
by Zacks Equity Research
Molina Healthcare (MOH) expects adjusted EPS to be at a minimum of $23.5 in 2024, which represents a year-over-year improvement of 12.5%.
DexCom (DXCM) Launches One+ Real-time CGM System in Europe
by Zacks Equity Research
DexCom (DXCM) unveils its new CGM system, Dexcom ONE+, which is set to provide easy and effective care to diabetic patients.
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
by Zacks Equity Research
Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.
Inspire Medical (INSP) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) U.S. region witnesses strong revenue growth in the fourth quarter.
Centene (CNC) Q4 Earnings Beat on Membership Growth, View Up
by Zacks Equity Research
Centene (CNC) expects adjusted EPS to be a minimum of $6.70 in 2024, higher than the 2023 figure of $6.68 per share.
Philips (PHG) Receives FDA Class 1 Recall for BrightView SPECT
by Zacks Equity Research
Philips (PHG) receives an FDA Class 1 recall for BrightView imaging systems.
PacBio's (PACB) New Kits to Boost Its Revio Sequencing System
by Zacks Equity Research
PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.
ELV vs. AVTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. AVTR: Which Stock Is the Better Value Option?
Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and McKesson (MCK) have performed compared to their sector so far this year.
BD (BDX) Q1 Earnings Surpass Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.